Analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report $0.10 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for AMAG Pharmaceuticals’ earnings, with estimates ranging from ($0.09) to $0.50. AMAG Pharmaceuticals posted earnings per share of $1.52 in the same quarter last year, which indicates a negative year-over-year growth rate of 93.4%. The company is scheduled to report its next quarterly earnings report on Tuesday, February 13th.

According to Zacks, analysts expect that AMAG Pharmaceuticals will report full year earnings of ($4.17) per share for the current financial year, with EPS estimates ranging from ($6.63) to ($1.43). For the next fiscal year, analysts forecast that the business will post earnings of ($2.33) per share, with EPS estimates ranging from ($6.91) to ($0.36). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for AMAG Pharmaceuticals.

Several equities research analysts recently commented on the stock. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Cantor Fitzgerald restated a “hold” rating and issued a $21.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Morgan Stanley reduced their price target on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, November 3rd. Finally, Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $23.38.

Several institutional investors and hedge funds have recently made changes to their positions in AMAG. Municipal Employees Retirement System of Michigan increased its stake in shares of AMAG Pharmaceuticals by 6.6% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock worth $152,000 after purchasing an additional 510 shares during the last quarter. Hartford Investment Management Co. acquired a new position in shares of AMAG Pharmaceuticals during the 3rd quarter worth $186,000. Cubist Systematic Strategies LLC acquired a new position in shares of AMAG Pharmaceuticals during the 3rd quarter worth $197,000. 361 Capital LLC acquired a new position in shares of AMAG Pharmaceuticals during the 3rd quarter worth $197,000. Finally, Aperio Group LLC acquired a new position in shares of AMAG Pharmaceuticals during the 3rd quarter worth $198,000.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up $0.70 during trading hours on Wednesday, hitting $15.30. 1,078,350 shares of the company traded hands, compared to its average volume of 1,154,300. The company has a current ratio of 1.59, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94. The stock has a market cap of $539.91, a P/E ratio of -2.52 and a beta of 0.79. AMAG Pharmaceuticals has a fifty-two week low of $11.93 and a fifty-two week high of $36.60.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Anticipate AMAG Pharmaceuticals, Inc. (AMAG) Will Post Earnings of $0.10 Per Share” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/03/zacks-brokerages-anticipate-amag-pharmaceuticals-inc-amag-will-post-earnings-of-0-10-per-share.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.